$ICUI

Sousa Ben sold $401K of ICUI

Sousa Ben (Chief Information Officer) sold 2,250 shares of ICU MEDICAL INC/DE (ICUI) at $178.32 ($0.40M total) on 2026-08-12.

Original reporting
SEC EDGAR · Sousa Ben
Published Aug 12, 2026, 8:33 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICUI
Neutral
medium confidence
Mentioned
$ICUI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICUINeutralLow
01

Why it matters

The newest fact is the specific open-market sale by the company’s CIO, including share count, price, and post-transaction holdings. No company performance, guidance, or corporate action is disclosed.

02

Market read

Traders may note insider selling as a sentiment datapoint, but there is no fundamental catalyst to drive repricing.

03

What to watch

Insider sales are frequently pre-planned or tax-related; without additional context (other insiders, buybacks, guidance), the signal is weak.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, after-hours disclosure window

Background

The article is a SEC Form 4 insider transaction disclosure for ICU Medical, Inc. (ICUI).

Company-level read

Ticker impact

$ICUINeutralMedium confidence
Context

ICU Medical disclosed a Form 4 showing CIO Sousa Ben sold 2,250 shares at $178.3152 on 2026-08-12 for about $401K.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamentals.

Evidence & confidence

Form 4 insider sales are common and often not predictive; the filing provides transaction details but no new operational, financial, or regulatory information.

Market effects

Minimal; insider selling in a single healthcare equipment name does not reset sector expectations.

None.

None.

Counterpoint

The sale could be routine liquidity or diversification, and the absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • ICU Medical, Inc.

    US-listed company whose insider transaction was reported on Form 4.

  • Sousa Ben

    Chief Information Officer who sold 2,250 shares on 2026-08-12.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICUIMed

ICU Medical rating upgraded by S&P on stronger credit metrics

S&P Global Ratings upgraded ICU Medical Inc. to 'BB' from 'BB-', citing improved credit metrics and strong operating performance. The company's adjusted leverage decreased to 3.1x in Q2 2026, with free operating cash flow exceeding expectations. ICU Medical used proceeds from asset sales and cash flow to reduce debt. S&P projects mid-single-digit revenue growth and margin improvement through 2027, with a stable outlook based on expected debt and cash flow metrics.

$ICUIMedAI 8/10

ICU Medical (ICUI) Q2 2026 Earnings Call Transcript

ICU Medical (ICUI) reported Q2 2026 revenue of $551.7M, up 1% reported and 6% organic excluding IV Solutions divestiture and currency. Infusion Systems revenue was $189.0M (+12% organic), Consumables $289.3M (+5% organic). Adjusted EBITDA was $110.0M (+10%). Full-year guidance raised to $415M-$435M EBITDA and $8.60-$9.00 EPS.

$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ:ICUI) shares rose 10.2% after the company reported Q2 results that beat Wall Street and lifted full-year guidance. Adjusted EPS was $2.37 vs $1.91 expected, revenue was $551.7 million vs forecasts, and free cash flow improved to $61.64 million. Full-year adjusted EPS guidance was raised to $8.80 (midpoint).

$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ: ICUI) shares rose 10.2% after the company reported Q2 adjusted EPS of $2.37, above the $1.91 consensus, and revenue of $551.7 million, above forecasts. Free cash flow improved to $61.64 million from -$8.49 million a year earlier. ICU Medical raised full-year adjusted earnings guidance to $8.80 per share (midpoint).

$ICUIMedAI 8/10

ICU Medical (NASDAQ:ICUI) Reports Strong Q2 CY2026

ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results. Revenue rose 1.5% year over year to $551.7 million, beating Wall Street’s revenue estimate by 3.5%. Non-GAAP adjusted EPS was $2.37, up from $2.10 and 23.8% above consensus. The stock rose 1.4% to $168.02 after the release.